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ão Paulo, Brazil; and Montreal, Quebec, Canada
bjectives We sought to investigate the performance and efﬁcacy of the third-generation polymer-
ree Vestasync-eluting stent (VES).
ackground Recent concerns regarding the long-term safety of drug-eluting stents have been
aised. Synthetic polymers have been associated with intensive inﬂammatory response and late
tent thrombosis. Newly developed, the VES combines a stainless steel platform with a nanothin-
icroporous hydroxyapatite surface coating impregnated with a polymer-free sirolimus formulation
55 m).
ethods In May 2007, 15 patients with single de novo lesion located in native coronary arteries
.0 to 3.5 mm in diameter and 14 mm in length were consecutively enrolled. Primary end points
ncluded in-stent late lumen loss and in-stent percent of obstruction at 4 months. Serial angi-
graphy and intravascular ultrasound were obtained at the index procedure and repeated at
-month follow-up.
esults Mean population age was 63.8 years; 33% of patients were diabetic. The left anterior de-
cending artery was the prevalent target vessel (47%). Reference vessel diameter and lesion length
ere 2.67  0.32 mm and 9.98  1.98 mm, respectively. The VES was successfully implanted in all
ases, and there were no procedure and in-hospital complications. Life-long aspirin and 6-month
lopidogrel therapy were prescribed for all patients. At 4 months, in-stent late lumen loss was
.30  0.25 mm and percent of stent obstruction was 2.8  2.2%. After up to 6 months of clinical
ollow-up, no major adverse cardiac event was registered.
onclusions The third-generation VES demonstrated excellent acute results in the treatment of de
ovo coronary lesions. Longer follow-up with a more complex subset of patients and lesions is re-
uired to conﬁrm these preliminary results. (J Am Coll Cardiol Intv 2008;1:545–51) © 2008 by the
merican College of Cardiology Foundation
rom the *Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil; and the †Montreal Heart Institute, Montreal, Quebec,
anada. Dr. Bonan and Dr. Alexandre Abizaid serve as consultants for MIV Therapeutics, Inc. James Hermiller, MD, served as
uest Editor for this paper.anuscript received April 25, 2008; revised manuscript received July 14, 2008, accepted July 28, 2008.
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546he efficacy of first-generation drug-eluting stents (DES) in
educing in-stent neointimal proliferation and therefore the
eed for repeat lesion revascularization is irrefutable (1,2).
owever, recent concerns regarding the long-term safety of
he Cypher (Cordis, Johnson & Johnson, Miami Lakes,
lorida) and Taxus (Boston Scientific Corporation, Natick,
assachusetts) stents have been raised (3–5).
The synthetic polymer, an essential component of these
rst-generation devices, has been associated with an inten-
ive inflammatory response (6). Animal histopathology and
x-vivo model analysis have shown exacerbated positive
essel remodeling, possibly caused by local response to the
olymer presence (7). Importantly, the association between
xacerbated vessel enlargement and very late DES throm-
osis has been recently demonstrated (8,9).
As a consequence, there is a major interest in developing
ew DES with greater flexibility, radiopacity, and better
afety profile. Recently developed, the Vestasync-eluting
tent (VES) (MIV Therapeutics, Inc., Atlanta, Georgia)
ombines a stainless steel platform with a nanothin-
microporous hydroxyapatite sur-
face coating impregnated with a
polymer-free sirolimus formula-
tion (55 g).
After positive preclinical stud-
ies, this first-in-human investi-
gation was conceived to evaluate
to investigate the safety, perfor-
mance, and efficacy of this third-
generation polymer-free DES.
Methods
Study population. In May 2007,
consecutive cohort of patients with single, de novo lesions
14 mm in length, located at native coronaries of diameters
rom 3.0 to 3.5 mm (by visual assessment) were consecu-
ively enrolled in this first-in-human study. Patients should
resent symptoms of angina (stable/unstable) or silent
schemia clearly documented through noninvasive assess-
ent. Patients treated within 72 h of an acute myocardial
nfarction and/or requiring more than 1 stent to treat the
arget lesion were excluded from this study. We also
xcluded patients who had heavily calcified lesions, lesions
t bifurcations or involving the ostium of the coronary
essel, severe left ventricular dysfunction (left ventricular
raction 30%), visible thrombus, and contraindications to
ny of the protocol medications.
The protocol was approved by the local Ethics Commit-
ee, and written informed consent was obtained from all
atients before inclusion in the study.
evice description. As with most DES systems, the Vesta-
ync hydroxyapatite nonpolymer-based sirolimus-eluting
bbreviations
nd Acronyms
K  creatine kinase
K-MB  creatine kinase-
yocardial band
ES  drug-eluting stent
VUS  intravascular
ltrasound
CA  quantitative coronary
ngiography
ES  Vestasync-eluting
tenttent system comprises 3 basic components: a platform, an tntiproliferative agent, and a drug carrier. In the following
ext, we briefly describe all 3 components used in this novel
evice.
tent platform. The GenX stainless steel (316 L) coronary
rtery stent (MIV Therapeutics, Inc.) is the new-generation
ariable geometry stent designed to minimize stent-induced
rterial injury (strut thickness  105 m). The GenX stent
s pre-mounted on a polyamide balloon catheter between 2
latinum iridium radio-opaque markers bands, nominally
.5 mm longer than the stent. Mounted stent length and
ocation are defined by radio-opaque marker.
onpolymeric drug carrier. The coating is composed of a
icroporous hydroxyapatite [Ca10(PO4)6(OH)2] underly-
ng coating. Sirolimus in a biocompatible oil-based formu-
ation is loaded into the microporous hydroxyapatite
oating.
Hydroxyapatite constitutes 70% of natural bone compo-
ition and therefore posseses excellent biocompatibility. It
oes not invoke an inflammatory reaction or foreign body
esponse and is therefore meant to improve the biocompat-
bility of metallic implants (10). Studies regarding the safety
f hydroxyapatite implants have shown no evidence of
oxicity. Long-term clinical data have shown the biocom-
atibility and safety of hydroxyapatite coatings in clinical
ettings (10–14). Furthermore, Pezzantini et al. (14) have
hown that in the presence of hydroxyapatite nanocrystals,
ndothelial cells maintain morphological and biochemical
arkers of a healthy functioning endothelium, without the
cquisition of proinflammatory phenotypes (14).
The hydroxyapatite coating thickness is on the order of
00 to 700 nm and possesses porosity in the range of 100 to
00 nm in diameter. The oil-based carrier of sirolimus
niformly fills the porosity of the hydroxyapatite coating
ithout adding to the thickness of the coating; therefore,
he final drug delivery coating remains under 1 m in
hickness. Figure 1 shows the scanning electron micrograph
ictures of the hydroxyapatite coating as well as the final
oating system. Because of the minimal coating thickness,
he amount of the carrier material for the drug is signifi-
antly minimized.
Current results have shown that the hydroxyapatite is
table for more than 4 months in an in vitro testing
nvironment. The in vivo expected lifetime of the hydroxy-
patite coating is in between 9 months and 1 year. After that
eriod, it is expected to crack and disappear (100% accord-
ng to pre-clinical data).
ntiproliferative agent sirolimus. Sirolimus (Rapamune), a
atural macrocyclic lactone, is a potent immunosuppressive
gent that was developed by Wyeth-Ayerst Laboratories
Madison, New Jersey) and approved by the Food and Drug
dministration (FDA) for the prophylaxis of renal trans-
lant rejection in 1999 (15). Sirolimus binds to an intracel-
ular receptor protein and elevates p27 levels, which leads to
he inhibition of cyclin/cyclin-dependent kinase complexes
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547nd, ultimately, induces cell-cycle arrest in the late G1
hase. It inhibits the proliferation of both rat and human
mooth muscle cells in vitro (16,17) and reduces intimal
hickening in models of vascular injury (18–20).
Regarding sirolimus kinetics in the VES, in vitro testing
n crimped and expanded stents at 37°C in 7.4 pH buffered
aline demonstrates a drug release rate (in micrograms per
ime point, not percentage of loaded drug) that is almost the
ame as that of the Cypher stent for the first hour.
hereafter, the release rate slows down to less than half the
ate of Cypher. By in vitro experimentation, it is calculated
hat 100% of the drug will be released from the stent in
pproximately 3 to 4 weeks.
rocedure. For the present study, the VES was available in
nly 2 diameters (3.0 and 3.5 mm) and a single length (19
m). The eluted dose of sirolimus was less than half of the
ose used in the Cypher stent (55 g vs. 140 g).
All interventions were performed according to the current
tandard guidelines. After mandatory predilation of the
arget lesion, stents were deployed with high pressure after
ilation.
Dual antiplatelet therapy including loading dose of aspi-
in (200 to 325 mg) and thienopyridine (clopidogrel 300
g) was started at least 24 h before the procedure. Post-
Figure 1. Main Components of the Vestasync Sirolimus-Eluting Stent Syste
Scanning electron micrographs of (A) microporous hydroxyapatite coating, (B)
hydroxyapatite ﬁlled with sirolimus formulation, and (D) cross section of the ﬁrocedural aspirin was continued indefinitely, and clopi- rogrel was maintained for 6 months (75 mg/day). During
he procedure, intravenous heparin (70 to 100 IU/kg) was
dministered after sheath insertion to maintain an activated
lotting time 250 s. Use of additional medications during
he procedure, including glycoprotein IIb/IIIa inhibitors,
as left to the operator’s discretion.
A 12-lead electrocardiogram was obtained: 1) before the
rocedure; 2) immediately afterward; and 3) 24 h later.
lood sample laboratory analysis included cardiac enzymes
reatine kinase (CK) and creatine kinase-myocardial band
CK-MB) before the procedure (24 h) and 12 to 18 h
fter treatment.
ollow-up. After discharge, patients were clinically followed
p by medical appointments at 1, 3, and 6 months. Addi-
ional clinical follow-up at 9, 12, and 24 months is expected
y protocol. Angiography and intravascular ultrasound
IVUS) follow-up was scheduled for 4 months after the
aseline procedure.
uantitative coronary angiography (QCA) analysis. Angio-
raphic studies were performed at baseline, after the proce-
ure, and at follow-up, in 2 orthogonal views, after the
ntracoronary administration of 100 to 200 g nitroglycerin.
he same angiographic angles performed at baseline were
section of the hydroxyapatite coating, (C) ﬁnal coating, including the
ating.m
crosseproduced at the subsequent studies. Digital angiograms
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548ere analyzed off line with the use of an automated
dge-detection system (QCA-CMS, Medis Medical Imag-
ng Systems, Nuenen, the Netherlands). Lesion morphology
as assessed by using standard criteria, and lesion complex-
ty was defined according to the modified American College
f Cardiology/American Heart Association (ACC/AHA)
lassification system (21). The contrast-filled catheter tip
as used for calibration.
Quantitative angiographic parameters included: 1) refer-
nce vessel diameter; 2) minimum lumen diameter; 3) lesion
ength; 4) percent diameter stenosis (difference between the
eference diameter and minimum lumen diameter divided
y the reference diameter and multiplied by 100); and 5) late
uminal loss (difference between minimum lumen diameter
t the end of the procedure and minimum lumen diameter
t follow-up). Quantitative analysis was performed in the
n-stent area (inside the stented segment) and in the
n-lesion segment, including the stented area as well as 5
m both proximally and distally to the stent. In-stent and
n-lesion restenoses were defined as50% diameter stenosis
t follow-up located within the stent and the target lesion,
espectively.
VUS analysis. The IVUS studies were performed immedi-
tely after the procedure and at follow-up, after intracoro-
ary administration of 100 to 200 g nitroglycerin.
All IVUS studies were performed with a motorized
utomatic transducer pullback system (0.5 mm/s) and com-
ercially available scanners (i-Lab, Boston Scientific Cor-
oration, Natick, Massachusetts) consisting of a rotating
0-MHz transducer catheter (Atlantis SR pro) with a
.6-F imaging sheath. The images were digitalized for
ff-line quantitative analysis according to the American
ollege of Cardiology’s Clinical Expert Consensus Doc-
ment on IVUS. Quantitative IVUS analysis was made
sing a commercially available computerized planimetry
rogram (EchoPlaque, INDEC Systems, Mountain View,
alifornia).
Quantitative parameters of lumen, stent, and vessel (ex-
ernal elastic membrane) cross-sectional areas were deter-
ined. The neointimal area was calculated as the stent area
inus the lumen area at follow-up. Late lumen area loss was
alculated as the minimum lumen area after initial stent
eployment minus the minimum lumen area within the
tented segment at follow-up. Lumen, stent, vessel, and
eointimal volumes were calculated using Simpson’s rule.
ercent of neointimal volume obstruction was determined
y the neointimal volume at follow-up divided by the
ollow-up stent volume and multiplied by 100.
Incomplete stent apposition was defined as1 stent strut
learly separated from the vessel wall with evidence of blood
peckles behind the struts, and was classified as follows: 1)
ersistent (when present both in the post-stent implantation
nd follow-up studies); 2) late acquired (when not present at
ost-stent implantation, but detectable at the follow-up ntudy); and 3) resolved (when present at post-stent implan-
ation, but not detectable at the follow-up study).
Both QCA and IVUS analyses were performed by inde-
endent core laboratories at Cardiovascular Research Cen-
er (São Paulo, Brazil).
tudy end points. The primary end points of this analysis
ere in-stent luminal late loss as measured by QCA and
n-stent percentage volume obstruction by IVUS, measured
t 4-month angiographic follow-up. Secondary end points
ncluded acute success (angiographic and procedure suc-
ess), cumulative rate of major adverse cardiac events up to
years, rates of target lesion and target vessel revascular-
zation up to 2 years, and in-stent volumetric neointimal
urden by IVUS at 4 and 8 months.
Device success was defined by the presence of residual
tenosis 20% in the treated segment, in the presence of
hrombolysis In Myocardial Infarction (TIMI) flow grade
after implantation of the VES. Procedure success was
efined by device success associated with no in-hospital
ajor adverse events. A major adverse cardiac event was
efined as death, nonfatal myocardial infarction (Q-wave
nd non–Q-wave), and need for repeat lesion revasculariza-
ion (by new percutaneous intervention or coronary artery
ypass graft surgery). All deaths were considered cardiac
nless a clear noncardiac reason was identified. Myocardial
nfarction was defined by an increase in the CK-MB twice
he upper the normal limit with or without new Q waves on
he electrocardiogram.
tatistical analysis. Continuous variables are expressed as
ean  SD. Comparisons between post-intervention and
ollow-up measurements were performed with a 2-tailed
aired t test. A p value  0.05 was considered statistically
ignificant.
esults
uring May 2007, a total of 15 consecutive patients who
atched the inclusion/exclusion criteria were treated with
he Vestasync eluting stent and included in this analysis.
he mean age was 63.8 years ( 1.4 years), and 40% were
omen. Diabetes mellitus was present in 33% of the cases.
he left anterior descending artery was the target vessel in
ost cases (47%) (Table 1).
All stents were successfully deployed, and all patients
ere discharged without complications 24 h after the
ercutaneous intervention. Enzymatic elevation (CK and
K-MB) was not observed among these patients.
Post-procedure and 4-month QCA and IVUS results are
isplayed in Tables 2 and 3. One IVUS study was deemed
nappropriate for analysis (poor image quality), and there-
ore the patient was excluded from the IVUS baseline/
ollow-up comparison. Binary restenosis (in-stent stenosis
50%) was not observed in any these patients by QCA, and
o patient had more than 10% neointimal proliferation at
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549VUS. Two cases of acute incomplete stent apposition were
bserved in the baseline procedure and were significantly
educed at 4-month follow-up. Figure 2 exemplifies the best
nd worst results of the patients enrolled in this study.
Table 1. Baseline Patient, Lesion, and Procedure Characteristics
Characteristics Patients (n  15)
Mean age, yrs 63.8  11.4
Female 6 (40%)
Hypertension 9 (60%)
Dyslipidemia 7 (47%)
Diabetes mellitus 5 (33%)
Smoking 7 (47%)
Family history of CAD 6 (40%)
Previous MI 7 (47%)
Previous CABG 2 (13%)
Treated coronary artery
LAD 7 (47%)
LCx 4 (25%)
RCA 4 (25%)
Lesion complexity*
Type A 1 (7%)
Type B1 3 (20%)
Type B2 11 (73%)
Pre-dilation 15 (100%)
Post-dilation 7 (47%)
Number of stents per lesion 1.0
Mean ﬁnal deployment pressure, atm 12.4  2.1
Pre-procedure QCA
Mean reference vessel diameter, mm 2.67  0.32
Mean lesion length, mm 9.98  1.98
Minimum lumen diameter, mm 0.98  0.29
Diameter of stenosis 63.5  9.90
Angiographic success 15 (100%)
Procedure success 15 (100%)
Values are mean  SD or n (%). *According to American College of Cardiology/American Heart
Association classification
CABG  coronary artery bypass graft; CAD  coronary artery disease; DS  diameter of
stenosis; LAD  left anterior descending artery; LCx  left circumflex coronary artery; MI 
myocardial infarction; RCA right coronary artery; QCA quantitative coronary angiography.
Table 2. Baseline (Post-Procedure) and 4-Month Quantitative Coronary
Analysis
Post-Procedure
(n  15)
4-Month Follow-Up
(n  15)
In-lesion MLD, mm 2.21 0.36 2.05 0.38
In-stent MLD, mm 2.64 0.31 2.34 0.33
In-lesion diameter of stenosis, % 20.5 9.0 23.6 8.8
In-stent diameter of stenosis, % 8.4 4.3 13.8 7.0
Acute gain, mm 1.66 0.34 N/A
In-lesion late loss, mm N/A 0.16 0.29
In-stent late loss, mm N/A 0.30 0.25
Values aremean SD. The p value was not significant for any comparison between baseline and
4-month results.rMLDminimum lumen diameter; N/A not applicable.At 6-month clinical follow-up, all patients were asymp-
omatic with negative results of noninvasive ischemia test-
ng. There were no major adverse clinical events, including
ardiac/noncardiac death, cerebrovascular accident, nonfatal
yocardial infarction, or stent thrombosis.
iscussion
he main finding of this first-in-human study with the
on–polymer-based VES is that sirolimus can be efficiently
elivered to the coronary artery without a durable polymer,
s demonstrated by the minimum neointimal growth noted
t QCA and IVUS.
The development of novel DES systems must be guided
y 2 main rationales: 1) to achieve an improved safety
rofile, and 2) to improve or at least keep the efficacy profile
t levels comparable to those of the existing DES devices.
The DES toxicity may be related mainly to 2 aspects:
ose/type of the antiproliferative agent delivered to the
oronary artery and presence/type of polymer used to carry
he antiproliferative drug. In this context, the novel VES
arries less than one-half of the dose of the first-generation
ypher sirolimus-eluting stent. As previously demonstrated
y Nakamura et al. (22), it is possible to keep the same
fficacy of the Cypher stent using 70% or even 45% of its
riginal dose. In a study conducted by that group with 44
atients treated with the Cypher stent at reduced doses,
ngiographic and ultrasonographic results were comparable
o those obtained after the full-dose Cypher implantation
22). Our current analysis supports their findings.
A few recent clinical reports have correlated the presence
f durable polymers to local vessel response (e.g., marked
ositive remodeling in the treated segment), and of more
mportance, some potentially life-threatening cases of late
nd very late stent thrombosis have been described. These
linical findings have also been associated with local inflam-
atory response, as noted in post-mortem studies (23,24).
At present, 4 different DES are FDA approved (Cypher,
axus, Endeavor, and Promus/Xience V). Apart from the
ndeavor, which uses a biocompatible polymer (phospho-
Table 3. Intravascular Ultrasound Measurements at Baseline and
4-Month Follow-Up
Measurement
Baseline
(n  14)
4-Month Follow-Up
(n  14)
Vessel volume, mm3 294.2 117.1 286.9 87.4
Stent volume, mm3 144.5 48.2 140.5 36.7
Lumen volume, mm3 144.7 48.4 136.3 34.2
In-stent neointimal volume, mm3 N/A 4.3 3.5
In-stent volume of obstruction, % N/A 2.8 2.2
Values aremean SD. The p value was not significant for any comparison between baseline and
4-month results.
N/A not applicable.ycholine) to carry the zotarolimus, the other 3 systems use
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550urable polymers. The Endeavor, though, is the DES that
licits more neointimal proliferation, as consistently dem-
nstrated in all clinical studies (roughly 0.6 mm) (25). The
ther 3 DES presented late loss ranging from 0.1 to 0.4 mm
n their clinical series (Fig. 3) (26–28). As demonstrated by
auri et al. (29), there are incremental steps in binary
estenosis as in-stent late loss increases. According to the
athematical model proposed by their group, a rise from
Figure 2. Examples From Our Initial Experience
Two examples of our ﬁrst-in-human series of patients treated with the Vestasy
(0.80 mm). Panel B demonstrates our best results (late lumen loss of 0.1 mm
Figure 3. Late Lumen Loss of Vestasync Stent Versus the
FDA-Approved DES
Late loss results reported for the Food and Drug Administration (FDA)–
approved drug-eluting stent (DES) in contrast to the ﬁndings of the current
analysis. When compared to the published results of other DES tested in
similar scenarios, the in-stent late loss of the Vestasync stent is equivalent
to that of the Endeavor and Taxus stents and slightly higher than that of
the Cypher and Xience/Promus stents. *Invasive follow-up done at 4
months. **Invasive follow-up done at 6 months. FIM  ﬁrst-in-man; SPIRITe
 Stroke Prevention in Reversible Ischemia Trial..2 to 0.4 mm would result in an increase in restenosis rate
y 3.1%, whereas an increase in late loss from 0.4 to 0.6 mm
ould result in an augmentation in the expected restenosis
ate by 6.4%.
The VES late loss of 0.30 mm situates this new device
mong the highest-efficacy DES, with the advantage of a
olymer-free system using less drug than first-generation
quivalents. Figure 2 exemplifies 2 cases of our preliminary
eries.
Currently ongoing, the multicenter Vestasync 2 trial will
ompare, in a randomized fashion, patients treated with the
ES (n  90) to its noneluted equivalent, the GenX stent
n  30).
tudy limitations. This study comprises a registry of only 15
atients with noncomplex coronary lesions with 6-month
linical follow-up. Considering the virtual absence of late
oss (by QCA) and neointimal formation (by IVUS) at
-month invasive follow-up, however, these results seem to
e very promising. Nine-month angiography and IVUS will
e performed in all patients to assess whether these prelim-
nary findings are sustained; moreover, patients will be
linically followed up for 3 years. The 4-month follow-up of
5 patients precludes any definite conclusion about the
ong-term safety of this device.
onclusions
he third-generation Vestasync hydroxyapatite non-
olymer-based sirolimus-eluting stent system was proved
easible and safe, and elicited minimum neointimal prolif-
nt. Panel A demonstrates the case with higher late lumen loss at 4 months
 follow-up; POST  post-procedure; PRE  pre-procedure.nc steration at 4-month follow-up. These favorable preliminary
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551esults require further confirmation by large, randomized,
ulticenter clinical studies with longer follow-up.
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